Metabolic syndrome prevalence and characteristics in Greek adults with familial combined hyperlipidemia

Metabolism: Clinical and Experimental

Volumn 56, Issue 1, 2007, Pages 135-141

  Skoumas, John ^a   Papadimitriou, Lambros ^a   Pitsavos, Christos ^a   Masoura, Constantina ^a   Giotsas, Nikolaos ^a   Chrysohoou, Christina ^a   Toutouza, Marina ^a   Panagiotakos, Demosthenes ^b   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HAROKOPIO UNIVERSITY   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT;

ADULT; AGE; AGED; ANTHROPOMETRY; ARTICLE; BIOCHEMISTRY; CLINICAL STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FAMILIAL HYPERLIPEMIA; FEMALE; GEOGRAPHIC DISTRIBUTION; GREECE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; POPULATION BASED CASE CONTROL STUDY; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GREECE; HUMANS; HYPERLIPIDEMIA, FAMILIAL COMBINED; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; TRIGLYCERIDES;

EID: 33845209360     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2006.09.007     Document Type: Article

References (37)

1. National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health, NIH Publication No. 01-3670, May 2001
2. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287 (2002) 356-359
3. Panagiotakos D.B., Pitsavos C., Chrysohoou C., et al. Impact of lifestyle habits on the prevalence of the metabolic syndrome among Greek adults from the ATTICA study. Am Heart J 147 (2004) 106-112
4. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
5. Van der Kallen C.J., Voors-Pette C., and De Bruin T.W.A. Abdominal obesity and expression of familial combined hyperlipidemia. Obes Res 12 (2004) 2054-2061
6. Veerkamp M.J., De Graaf J., and Stalenhoef A.F.H. Role of insulin resistance in familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 25 (2005) 1026-1031
7. Carmena R., Ascaso J.F., and Real J.T. Impact of obesity in primary hyperlipidemias. Nutr Metab Cardiovasc Dis 11 (2001) 354-359
8. Castro C.M., de Bruin T.W., de Valk H.W., et al. Impaired fatty acid metabolism in familial combined hyperlipidemia. A mechanism associating hepatic apolipoprotein B overproduction and insulin resistance. J Clin Invest 92 (1993) 160-168
9. Pihlajamaki J., Karjalainen L., Karhapaa P., et al. Impaired free fatty acid suppression during hyperinsulinemia is a characteristic finding in familial combined hyperlipidemia, but insulin resistance is observed only in hypertriglyceridemic patients. Arterioscler Thromb Vasc Biol 20 (2000) 164-170
10. Carr M.C., and Brunzell J.D. Abdominal obesity and dyslipidemia in the metabolic syndrome: importance of type 2 diabetes and familial combined hyperlipidemia in coronary artery disease risk. J Clin Endocrinol Metab 89 (2004) 2601-2607
11. Ayyobi A.F., McGladdery S.H., McNeely M.J., et al. Small, dense LDL and elevated apolipoprotein B are the common characteristics for the 3 major lipid phenotypes of familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 23 (2003) 1289-1294
12. Ayyobi A.F., and Brunzell J.D. Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am J Cardiol 92 suppl (2003) 27J-33J
13. Gaddi A., Galetti C., Pauciullo P., et al. Familial combined hyperlipoproteinemia: experts' panel position on diagnostic criteria for clinical practice. Committee of experts of the Atherosclerosis and Dysmetabolic Disorders Study Group. Nutr Metab Cardiovasc Dis 9 (1999) 304-311
14. de Graaf J., van der Vleuten G., and Stalenhoef A.F. Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia. Semin Vasc Med 4 (2004) 229-240
15. Hopkins P.N., Heiss G., Ellison C., et al. Coronary artery disease risk in familial combined hyperlipidemia and familial hypertriglyceridemia. A case control comparison from the National Heart, Lung and Blood Institute Family Heart Study. Circulation 108 (2003) 519-523
16. Rifkind B.M., and Segal P. Lipid research clinics program reference values for hyperlipidemia and hypolipidemia. JAMA 250 (1983) 1869-1872
17. Pitsavos C., Panagiotakos D.B., Chrysohoou C., et al. Epidemiology of cardiovascular risk factors in Greece: aims, design and baseline characteristics of the ATTICA study. BMC Public Health 3 (2003) 32
18. Pairitz G., Davignon J., Mailloux H., et al. Sources of interindividual variation in the quantitative levels of apolipoprotein B in pedigrees ascertained through a lipid clinic. Am J Hum Genet 43 (1988) 311-321
19. Austin M.A., Horowitz H., Wijsman E., et al. Bimodality of plasma apolipoprotein B levels in familial combined hyperlipidemia. Atherosclerosis 92 (1992) 67-77
20. Bredie S.J., Tack C.J., Smits P., et al. Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler Thromb Vasc Biol 17 (1997) 1465-1471
21. Purnell J.Q., Kahn S.E., Schwartz R.S., et al. Relationship of insulin sensitivity and ApoB levels to intra-abdominal fat in subjects with familial combined hyperlipidemia. Arterioscler Thromb Vasc Biol 21 (2001) 567-572
22. Anand S.S., Yi Q., Gerstein H., et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108 (2003) 420-425
23. Gu D., Reynolds K., Wu X., et al. Prevalence of the metabolic syndrome and overweight among adults in China. Lancet 365 (2005) 1398-1405
24. Ascano J.F., Merchante A., Lorente R.I., et al. A study of insulin resistance using the minimal model in nondiabetic familial combined hyperlipidemic patients. Metabolism 47 (1998) 508-513
25. Shoulders C.C., and Naoumova R.P. USF1 implicated in the aetiology of familial combined hyperlipidaemia and the metabolic syndrome. Trends Mol Med 10 (2004) 362-365
26. Shoulders C.C., Jones E.L., and Naoumova R.P. Genetics of familial combined hyperlipidemia and risk of coronary heart disease. Hum Mol Genet 13 Review Issue 1 (2004) 149-160
27. Pajukanta P., Lilja H.E., Sinsheimer J.S., et al. Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet 36 (2004) 371-376
28. Assmann G., and Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience): Prospective Cardiovascular Munster study. Am J Cardiol 70 (1992) 733-737
29. Garvey W.T., Kwon S., Zheng D., et al. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes 52 (2003) 453-462
30. Rosenson R.S., Otvos J.D., and Freedman D.S. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am J Cardiol 90 (2002) 89-94
31. Alexander C.M., Landsman P.B., Teutsch S.M., et al. Third National Health and Nutrition Examination Survey (NHANES III); National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
32. Lakka H.M., Laaksonen D.E., Lakka T.A., et al. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
33. Isomaa B., Almgren P., Tuomi T., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (2001) 683-689
34. Stern M.P., Williams K., and Hunt K.J. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl 6 (2005) 3-6
35. Pei W.D., Sun Y.H., Rou W.J., et al. Apolipoprotein B is associated with metabolic syndrome in Chinese pedigrees with familial hyperlipidemia. Zhonghua Yi Xue Za Zhi 85 (2005) 313-317
36. Sattar N., Williams K., Sniderman A.D., et al. Comparison of the associations of apolipoprotein B and non-high-density lipoprotein cholesterol with other cardiovascular risk factors in patients with the metabolic syndrome in the Insulin Resistance Atherosclerosis Study. Circulation 110 (2004) 2687-2693
37. O'Donovan G., Owen A., Kearney E.M., et al. Cardiovascular disease risk factors in habitual exercisers, lean sedentary men and abdominally obese sedentary men. Int J Obes (Lond) 29 (2005) 1063-1069